NCT07444710 2026-03-19
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
Clinical Trials
49 trialsNCT07332507 2026-03-18
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
National Cancer Institute (NCI)
Phase 1 Not yet recruiting
NCT07388563 2026-03-18
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07478848 2026-03-18
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
Phase 1 Not yet recruiting
NCT07133997 2026-03-13
Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07444632 2026-03-11
Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07454863 2026-03-06
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
Dizal Pharmaceuticals
Phase 1 Not yet recruiting
NCT07451054 2026-03-05
CD45BE-HSPC + CART-45 Cells
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07101328 2026-03-04
BAF_FRontier-1
Eli Lilly and Company
Phase 1 Not yet recruiting
NCT07220993 2026-03-04
Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT07428486 2026-02-23
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07422610 2026-02-20
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Novartis
Phase 1 Not yet recruiting
NCT07424833 2026-02-20
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Phase 1 Not yet recruiting
NCT07383233 2026-02-03
CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma
Tianjin First Central Hospital
Phase 1 Not yet recruiting
NCT07367685 2026-01-26
Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
Phase 1 Not yet recruiting
NCT07049432 2026-01-23
CARMEN-803
University of Utah
Phase 1 Not yet recruiting
NCT07343934 2026-01-15
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07334574 2026-01-13
XP-006
Ruijin Hospital
Phase 1 Not yet recruiting
NCT07335328 2026-01-13
Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT05544968 2026-01-12
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Not yet recruiting
NCT07316920 2026-01-06
A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Affiliated Hospital of Jiangsu University
Phase 1 Not yet recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT07283640 2025-12-22
A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07254793 2025-11-28
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
Phase 1 Not yet recruiting
NCT06970496 2025-11-20
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT07234045 2025-11-18
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07225439 2025-11-06
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Case Comprehensive Cancer Center
Phase 1 Not yet recruiting
NCT07192471 2025-09-25
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1 Not yet recruiting
NCT07169565 2025-09-11
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT07113496 2025-08-13
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1 Not yet recruiting
NCT07068906 2025-07-16
A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT06385522 2025-07-08
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
Boston Immune Technologies and Therapeutics
Phase 1 Not yet recruiting
NCT04419909 2025-07-02
Retreatment With CTL019/CTL119
University of Pennsylvania
Phase 1 Not yet recruiting
NCT07043218 2025-06-29
A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1 Not yet recruiting
NCT07024147 2025-06-17
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute
Phase 1 Not yet recruiting
NCT07020533 2025-06-13
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT06894693 2025-03-25
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Not yet recruiting
NCT06712173 2024-12-02
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Not yet recruiting
NCT06696846 2024-11-20
CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Not yet recruiting
NCT06647329 2024-10-17
CAR-T Therapy
Zhengzhou University
Phase 1 Not yet recruiting
NCT06641024 2024-10-15
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL
Chongqing Precision Biotech Co., Ltd
Phase 1 Not yet recruiting
NCT06318884 2024-03-22
A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
Sinocelltech Ltd.
Phase 1 Not yet recruiting
NCT06314828 2024-03-18
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
Guangdong Ruishun Biotech Co., Ltd
Phase 1 Not yet recruiting
NCT05788107 2023-08-09
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT05900089 2023-06-12
Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Henan Cancer Hospital
Phase 1 Not yet recruiting
NCT05381181 2023-01-27
Safety and Efficacy Evaluation of Next-generation CD19-UCART
Bioray Laboratories
Phase 1 Not yet recruiting
NCT05391490 2022-05-26
KCAT19
University College, London
Phase 1 Not yet recruiting
NCT04595162 2020-10-20
A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Peking University Third Hospital
Phase 1 Not yet recruiting